Jake Simson is a Partner at RA Capital Management. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Janux Therapeutics, Tyra Biosciences, AavantiBio, and DiCE Molecules. Previously, Jake covered solid tumor oncology landscapes. Jake holds a B.S. in materials science and engineering from MIT and a Ph.D. in biomedical engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.